公开(公告)号：EP3795579B1

公开(公告)日：2024-03-20

申请号：EP18932609.3

申请日：2018-12-24

Inventor： ZHANG, Baotang ,  TAN, Jiazhong

IPC: C07J17/00 ,  C07H17/00 ,  A23L27/10 ,  A23L5/00 ,  A23L19/00 ,  A23L27/30 ,  A23N1/02 ,  A61K8/9789 ,  A61Q19/00

公开(公告)号：EP4308581A1

公开(公告)日：2024-01-24

申请号：EP22714652.9

申请日：2022-03-10

Applicant: Eli Lilly and Company

Inventor： CASSIDY, Kenneth Charles ,  KATYAYAN, Kishore Kumar

IPC: C07H17/00 ,  C07D491/052 ,  A61K31/436 ,  A61P35/00

公开(公告)号：EP4103576A1

公开(公告)日：2022-12-21

申请号：EP21705454.3

申请日：2021-02-10

Applicant: Glycoscience, S.L.

Inventor： SUTTON, Peter William

IPC: C07H15/18 ,  C07H15/04 ,  C07H15/20 ,  C07H17/00 ,  C07H1/00 ,  A01N43/16 ,  A61K8/60 ,  A01P17/00

公开(公告)号：EP3983781A1

公开(公告)日：2022-04-20

申请号：EP20822318.0

申请日：2020-06-06

Applicant: Agilent Technologies, Inc.

Inventor： HAXO, Francis

IPC: G01N21/64 ,  C07H17/00

公开(公告)号：EP3037428B1

公开(公告)日：2020-09-23

申请号：EP13891795.0

申请日：2013-11-01

Applicant: Pulike Biological Engineering Inc.

Inventor： LIU, Xingjin ,  ZHANG, Xuke

IPC: C07H17/08 ,  C07H17/00 ,  A61K31/7052 ,  A61K31/706

公开(公告)号：EP2900678B1

公开(公告)日：2020-09-02

申请号：EP13745375.9

申请日：2013-07-24

Applicant: Centre National de la Recherche Scientifique (C.N.R.S.) ,  Université de Nantes ,  Université de Picardie Jules Verne ,  Université Lille 1 - Sciences Et Technologies ,  Université d'Auvergne Clermont 1

Inventor： BOUCKAERT, Julie ,  GOUIN, Sébastien ,  DENIAUD, David ,  BILYY, Rostyslav ,  DUMYCH, Tetiana ,  SIVIGNON, Adeline ,  DARFEUILLE-MICHAUD, Arlette

IPC: C07H15/26 ,  C07H17/00 ,  C07H19/06 ,  A61P31/04 ,  A61K47/61

公开(公告)号：EP3563849A3

公开(公告)日：2020-02-12

申请号：EP19172666.0

申请日：2013-10-22

Applicant: The General Hospital Corporation

Inventor： ELMALEH, David R.

IPC: A61K31/4162 ,  A61K31/70 ,  C07D471/00 ,  C07D498/00 ,  C07H5/02 ,  C07H17/00 ,  A61P25/28 ,  A61P25/00

Abstract: The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.

公开(公告)号：EP1723159B1

公开(公告)日：2019-06-12

申请号：EP05723790.1

申请日：2005-02-25

Applicant: Melinta Therapeutics, Inc.

Inventor： FARMER, Jay, J. ,  BHATTACHARJEE, Ashoke ,  CHEN, Yi ,  GOLDBERG, Joel, A. ,  IPPOLITO, Joseph, A. ,  KANYO, Zoltan, F. ,  LOU, Rongliang ,  OYELERE, Adegboyega, K. ,  SHERER, Edward, C. ,  SUTCLIFFE, Joyce, A. ,  WANG, Deping ,  WU, Yusheng ,  DU, Yanming

IPC: C07H17/00 ,  C07H17/08

公开(公告)号：EP3423462A1

公开(公告)日：2019-01-09

申请号：EP17760582.1

申请日：2017-02-28

Applicant: Dow Agrosciences LLC

Inventor： FOSKEY, Takiya J.

IPC: C07H17/00 ,  B01J23/46

公开(公告)号：EP3406619A1

公开(公告)日：2018-11-28

申请号：EP16885495.8

申请日：2016-01-18

Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.

Inventor： YIN, Mingxing ,  WU, Dongdong ,  WEN, Weijiang

IPC: C07H17/00 ,  C07H17/08 ,  C07H1/00

CPC classification number: C07H1/00 ,  C07H17/00 ,  C07H17/08

Abstract: Disclosed are a method and an intermediate for preparing a tulathromycin. The method comprises the following step: in an organic solvent, subjecting a compound represented by formula (II) and an n-propylamine to a ring-opening addition shown below to obtain a tulathromycin represented by formula (I), wherein the organic solvent is a 1,2-propandiol. Tulathromycin obtained using the method has a high purity, with an HPLC purity being 95% and above, and up to 99% and above, satisfying a required purity for preparing a tulathromycin as a pharmaceutical formulation. The method has a high yield, is simple to operate, and is more suitable for industrial production.